NIM1K

Summary

NIM1K (NIM1 serine/threonine protein kinase, HGNC:28646) is a protein-coding gene on chromosome 5p12, encoding Serine/threonine-protein kinase NIM1 (Q8IY84).

Enables ATP binding activity; magnesium ion binding activity; and protein serine/threonine kinase activity. Involved in protein phosphorylation.

Source: NCBI Gene 167359 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 59 total
• Druggable target: yes — 11 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_153361

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28646
Approved symbol	NIM1K
Name	NIM1 serine/threonine protein kinase
Location	5p12
Locus type	gene with protein product
Status	Approved
Aliases	MGC42105, NIM1
Ensembl gene	ENSG00000177453
Ensembl biotype	protein_coding
Entrez	167359

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000326035, ENST00000440285, ENST00000509362, ENST00000512796, ENST00000513797, ENST00000889542, ENST00000889543, ENST00000889544, ENST00000889545, ENST00000945659, ENST00000945660

RefSeq mRNA: 1 — MANE Select: NM_153361 NM_153361

CCDS: CCDS3943

Canonical transcript exons

ENST00000326035 — 4 exons

Exon	Start	End
ENSE00001268305	43277057	43277325
ENSE00001268313	43192225	43192411
ENSE00001268319	43279980	43280850
ENSE00001268327	43245082	43246067

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 93.45.

FANTOM5 (CAGE): breadth broad, TPM avg 0.9179 / max 51.1071, expressed in 256 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56333	0.9179	256

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	93.45	gold quality
Brodmann (1909) area 23	UBERON:0013554	88.74	gold quality
endothelial cell	CL:0000115	87.60	gold quality
primary visual cortex	UBERON:0002436	85.67	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.22	gold quality
superior frontal gyrus	UBERON:0002661	83.84	gold quality
prefrontal cortex	UBERON:0000451	83.77	gold quality
entorhinal cortex	UBERON:0002728	83.42	gold quality
occipital lobe	UBERON:0002021	83.04	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.99	gold quality
frontal cortex	UBERON:0001870	82.95	gold quality
Brodmann (1909) area 46	UBERON:0006483	82.91	gold quality
postcentral gyrus	UBERON:0002581	82.68	gold quality
neocortex	UBERON:0001950	82.49	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.47	gold quality
caudate nucleus	UBERON:0001873	82.31	gold quality
cerebral cortex	UBERON:0000956	82.14	gold quality
right frontal lobe	UBERON:0002810	81.72	gold quality
parietal lobe	UBERON:0001872	81.70	gold quality
nucleus accumbens	UBERON:0001882	81.67	gold quality
temporal lobe	UBERON:0001871	81.58	gold quality
putamen	UBERON:0001874	81.43	gold quality
forebrain	UBERON:0001890	81.08	gold quality
anterior cingulate cortex	UBERON:0009835	80.96	gold quality
cartilage tissue	UBERON:0002418	80.89	gold quality
ventricular zone	UBERON:0003053	80.48	gold quality
amygdala	UBERON:0001876	80.41	gold quality
Ammon’s horn	UBERON:0001954	80.10	gold quality
epithelial cell of pancreas	CL:0000083	80.09	gold quality
brain	UBERON:0000955	79.58	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.24
E-MTAB-7381	no	71.28
E-MTAB-6142	no	2.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting NIM1K, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-1285-5P	98.01	68.71	779
HSA-MIR-2355-3P	96.84	68.54	909

Literature-anchored findings (GeneRIF, showing 1)

• PDE6D Mediates Trafficking of Prenylated Proteins NIM1K and UBL3 to Primary Cilia. (PMID:36672247)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nim1kb	ENSDARG00000079031
mus_musculus	Nim1k	ENSMUSG00000095930
rattus_norvegicus	Nim1k	ENSRNOG00000016353
drosophila_melanogaster	CG4629	FBGN0031299
caenorhabditis_elegans		WBGENE00009867

Paralogs (17): NUAK1 (ENSG00000074590), PRKAA1 (ENSG00000132356), TSSK4 (ENSG00000139908), HUNK (ENSG00000142149), SIK1 (ENSG00000142178), BRSK1 (ENSG00000160469), SIK3 (ENSG00000160584), PRKAA2 (ENSG00000162409), TSSK3 (ENSG00000162526), NUAK2 (ENSG00000163545), SNRK (ENSG00000163788), MELK (ENSG00000165304), SIK2 (ENSG00000170145), BRSK2 (ENSG00000174672), TSSK6 (ENSG00000178093), TSSK2 (ENSG00000206203), TSSK1B (ENSG00000212122)

Protein

Protein identifiers

Serine/threonine-protein kinase NIM1 — Q8IY84 (reviewed: Q8IY84)

Alternative names: NIM1 serine/threonine-protein kinase

All UniProt accessions (1): Q8IY84

UniProt curated annotations — full annotation on UniProt →

Activity regulation. Activated by phosphorylation at Thr-229, probably by autophosphorylation.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.

RefSeq proteins (1): NP_699192* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR049571	NIM1K_STKc	Domain

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (15 total): sequence variant 6, mutagenesis site 2, binding site 2, chain 1, domain 1, region of interest 1, active site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IY84-F1	82.63	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 196 (proton acceptor)

Ligand- & substrate-binding residues (2): 80–88; 103

Post-translational modifications (1): 229

Mutagenesis-validated functional residues (2):

Position	Phenotype
229	loss of autophosphorylation and kinase activity.
229	constitutively active.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, BENPORATH_ES_WITH_H3K27ME3, HNF3ALPHA_Q6, FOXO4_01, FOXO1_01, GGCNKCCATNK_UNKNOWN, MCAATNNNNNGCG_UNKNOWN, GGARNTKYCCA_UNKNOWN, HFH3_01, RFX1_02, EVI1_04, TGGAAA_NFAT_Q4_01, TAATTA_CHX10_01, GOMF_MAGNESIUM_ION_BINDING, GOMF_PROTEIN_KINASE_ACTIVITY

GO Biological Process (2): protein phosphorylation (GO:0006468), intracellular signal transduction (GO:0035556)

GO Molecular Function (9): magnesium ion binding (GO:0000287), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), kinase activity (GO:0016301), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
phosphorylation	1
protein modification process	1
intracellular anatomical structure	1
signal transduction	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cation binding	1

Protein interactions and networks

STRING

1253 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIM1K	PCP4L1	A6NKN8	459
NIM1K	TPCN1	Q9ULQ1	454
NIM1K	PLA2G4D	Q86XP0	430
NIM1K	CCDC152	Q4G0S7	429
NIM1K	ZBTB35	P52739	419
NIM1K	WEE1	P30291	415
NIM1K	TNK2	Q07912	408
NIM1K	GPR26	Q8NDV2	403
NIM1K	MYBPC2	Q14324	400
NIM1K	RIMS3	Q9UJD0	399
NIM1K	AMPD3	Q01432	392
NIM1K	MBIP	Q9NS73	386
NIM1K	SCNN1G	P51170	385
NIM1K	SLC12A7	Q9Y666	377
NIM1K	ATP4A	P20648	361

IntAct

3 interactions, top by confidence:

A	B	Type	Score
AURKB	SEC16A	psi-mi:“MI:0914”(association)	0.570
NIM1K	PDE6D	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): NIM1K (Affinity Capture-MS), NIM1K (Affinity Capture-RNA), NIM1K (Synthetic Lethality), PDE6D (Affinity Capture-MS), DNAJB6 (Affinity Capture-MS), GNB2L1 (Affinity Capture-MS), BASP1 (Affinity Capture-MS), SEPT9 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A0AUV4, A1A5Q6, A1A5R7, A2KF29, B1WAS2, C0HKC8, C0HKC9, D3ZML2, O60285, O74536, O88831, O88866, P41279, P51956, P57058, P97756, Q20443, Q2T9U5, Q5R7G9, Q5XHI9, Q60670, Q63562, Q641K5, Q66HE5, Q68UT7, Q6P431, Q6VZ17, Q7T0B0, Q7T0B1, Q7TNJ7, Q7TNL4, Q8BHI9, Q8BZN4, Q8C078, Q8C0N0, Q8C0V7, Q8C0X8, Q8CIP4, Q8IY84, Q8K4K4

Diamond homologs: A0AUV4, A1A5Q6, A2KF29, A2XFF4, A8WYE4, B2DD29, B8BBT7, C0HKC8, C0HKC9, F1QGZ6, O08678, O08679, O22932, O74536, O94168, P06782, P0DP15, P25389, P27448, P45894, P52497, P54645, P54646, P57059, P92958, Q00372, Q02723, Q03141, Q05512, Q09137, Q0D4B2, Q12152, Q12263, Q13131, Q14680, Q19469, Q21017, Q28948, Q28GW8, Q2RAX3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NIM1K	“down-regulates activity”	WEE1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1217 predictions. Top by Δscore:

Variant	Effect	Δscore
5:43192410:AGG:A	donor_loss	1.0000
5:43192411:GGTA:G	donor_loss	1.0000
5:43192412:G:GA	donor_loss	1.0000
5:43192413:T:G	donor_loss	1.0000
5:43277055:A:AG	acceptor_gain	1.0000
5:43277056:G:GG	acceptor_gain	1.0000
5:43277056:GAAA:G	acceptor_gain	1.0000
5:43277056:GAAAA:G	acceptor_gain	1.0000
5:43277176:G:GT	donor_gain	1.0000
5:43277214:G:GT	donor_gain	1.0000
5:43277217:G:GG	donor_gain	1.0000
5:43279977:CA:C	acceptor_loss	1.0000
5:43279978:A:AG	acceptor_gain	1.0000
5:43279978:A:C	acceptor_loss	1.0000
5:43279978:AGCAT:A	acceptor_gain	1.0000
5:43279979:G:GA	acceptor_gain	1.0000
5:43279979:G:GT	acceptor_loss	1.0000
5:43279979:GC:G	acceptor_gain	1.0000
5:43279979:GCA:G	acceptor_gain	1.0000
5:43279979:GCAT:G	acceptor_gain	1.0000
5:43279979:GCATG:G	acceptor_gain	1.0000
5:43192408:GAAG:G	donor_gain	0.9900
5:43192412:G:GG	donor_gain	0.9900
5:43277054:CA:C	acceptor_loss	0.9900
5:43277055:A:G	acceptor_loss	0.9900
5:43277056:G:GA	acceptor_loss	0.9900
5:43277056:GA:G	acceptor_gain	0.9900
5:43277056:GAA:G	acceptor_gain	0.9900
5:43277181:G:GA	donor_gain	0.9900
5:43279976:A:AG	acceptor_gain	0.9900

AlphaMissense

2877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:43246028:T:C	F85L	1.000
5:43246030:C:A	F85L	1.000
5:43246030:C:G	F85L	1.000
5:43277073:G:C	K103N	1.000
5:43277073:G:T	K103N	1.000
5:43280002:G:C	R195T	1.000
5:43280002:G:T	R195I	1.000
5:43280005:A:C	D196A	1.000
5:43280005:A:G	D196G	1.000
5:43280005:A:T	D196V	1.000
5:43280006:T:A	D196E	1.000
5:43280006:T:G	D196E	1.000
5:43280010:A:G	K198E	1.000
5:43280011:A:T	K198I	1.000
5:43280012:A:C	K198N	1.000
5:43280012:A:T	K198N	1.000
5:43280019:A:C	N201H	1.000
5:43280021:T:A	N201K	1.000
5:43280021:T:G	N201K	1.000
5:43280059:A:C	D214A	1.000
5:43280059:A:T	D214V	1.000
5:43280067:T:C	F217L	1.000
5:43280069:C:A	F217L	1.000
5:43280069:C:G	F217L	1.000
5:43280113:G:A	G232E	1.000
5:43280176:A:C	D253A	1.000
5:43280181:T:A	W255R	1.000
5:43280181:T:C	W255R	1.000
5:43280190:G:T	G258W	1.000
5:43280227:C:A	P270Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000036100 (5:43193236 G>A), RS1000036411 (5:43267201 T>C), RS1000092958 (5:43255673 C>G), RS1000184335 (5:43206530 G>A,C), RS1000239168 (5:43236065 G>A,C,T), RS1000286576 (5:43277367 T>C), RS1000287016 (5:43247963 G>C,T), RS1000323842 (5:43263069 C>A), RS1000494036 (5:43241705 TTTA>T), RS1000511693 (5:43228782 G>A,T), RS1000519156 (5:43258672 G>A), RS1000576124 (5:43263881 C>T), RS1000597452 (5:43205005 C>T), RS1000617469 (5:43212624 A>C), RS1000662795 (5:43218437 A>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010988_88	Adult body size	1.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3542 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

11 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 117,911 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL535	SUNITINIB	4	79,020
CHEMBL601719	CRIZOTINIB	4	14,403
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL1721885	SU-014813	2	363
CHEMBL475251	R-406	2	762
CHEMBL513909	BI-2536	2	895
CHEMBL1908394	GSK-461364	1	1,093
CHEMBL1908397	KW-2449	1	622

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NIM1 subfamily

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 89S [PMID: 19115845]	Inhibition	5.4	pIC50

ChEMBL bioactivities

21 potent at pChembl≥5 of 21 total, top 19 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.04	IC50	91.5	nM	STAUROSPORINE
6.89	IC50	129	nM	STAUROSPORINE
6.85	Kd	140	nM	STAUROSPORINE
6.83	IC50	147	nM	STAUROSPORINE
6.18	Kd	660	nM	R-406
6.11	Kd	770	nM	BI-2536
6.07	Kd	850	nM	SUNITINIB
6.07	Kd	850	nM	DOVITINIB
5.96	Kd	1100	nM	SU-014813
5.96	Kd	1100	nM	KW-2449
5.82	Kd	1500	nM	BOSUTINIB
5.75	Kd	1800	nM	LESTAURTINIB
5.58	Kd	2600	nM	TAE-684
5.36	IC50	4398	nM	CHEMBL5086901
5.36	Kd	4400	nM	FEDRATINIB
5.34	Kd	4600	nM	CRIZOTINIB
5.19	Kd	6400	nM	CHEMBL386051
5.19	Kd	6400	nM	GSK-461364
5.06	Kd	8700	nM	PHA-665752

PubChem BioAssay actives

21 with measured affinity, of 183 total; 16 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715238: Inhibition of human NIM1 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	ic50	0.0915	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624728: Binding constant for NIM1 kinase domain	kd	0.6600	uM
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	624728: Binding constant for NIM1 kinase domain	kd	0.7700	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	624728: Binding constant for NIM1 kinase domain	kd	0.8500	uM
Sunitinib	507649: Binding affinity to NIM1	kd	0.8500	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	624728: Binding constant for NIM1 kinase domain	kd	1.1000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624728: Binding constant for NIM1 kinase domain	kd	1.1000	uM
Bosutinib	624728: Binding constant for NIM1 kinase domain	kd	1.5000	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507649: Binding affinity to NIM1	kd	1.8000	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624728: Binding constant for NIM1 kinase domain	kd	2.6000	uM
5-cyclopropyl-4-N-[2-(1H-imidazol-5-yl)ethyl]-2-N-[3-methyl-1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrimidine-2,4-diamine	1823767: Inhibition of full length recombinant human NIM1 using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay	ic50	4.3980	uM
Fedratinib	624728: Binding constant for NIM1 kinase domain	kd	4.4000	uM
Crizotinib	624728: Binding constant for NIM1 kinase domain	kd	4.6000	uM
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide	624728: Binding constant for NIM1 kinase domain	kd	6.4000	uM
6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one	624728: Binding constant for NIM1 kinase domain	kd	6.4000	uM
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	624728: Binding constant for NIM1 kinase domain	kd	8.7000	uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation, affects methylation	3
sotorasib	affects cotreatment, decreases expression	1
butyraldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
pentanal	increases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Aldehydes	increases expression	1
Carbamazepine	affects expression	1
Estradiol	affects cotreatment, increases expression	1
Methapyrilene	decreases methylation	1
Oxygen	increases expression	1
Rotenone	decreases expression	1
Silicon Dioxide	decreases expression	1
Thiram	increases expression	1
Valproic Acid	increases expression	1
Cadmium Chloride	decreases expression	1

ChEMBL screening assays

119 unique, capped per target: 119 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1011036	Binding	Inhibition of NIM1	First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.